CeaproTSXV: CZO

Ceapro announces 2006 second quarter financial results

· Issued by Ceapro via CNW
EDMONTON, Aug. 23 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
second quarter financial results for 2006. Revenue from product sales rose 23%
to $1.8 million in the first six months of 2006, resulting in income from
operations of $133,000, and a net loss of $55,000. In the second quarter of
2006, Ceapro generated income from operations of $115,000, more than doubling
the $50,000 generated in the second quarter in 2005. This resulted in a net
loss of $3,000 in the quarter; $(0.00)/share.
"We have sold more active ingredients in each of the first two quarters
than ever before, and the second quarter set a new record for active
ingredient sales of $929,000," stated Dr. Mark Redmond, President and CEO of
Ceapro. "The expansion of sales to existing customers and the introduction of
new products to new customers have boosted sales of active ingredients, which
are up 27% over the second quarter of last year. This success comes from
strong relationships with our partners and the dedication and hard work of the
Ceapro manufacturing team. We are encouraged with third quarter orders and
look forward to growing sales throughout 2006."
Gross margins were strong at 58% of sales revenue, primarily as a result
of higher product sales, greater economies of scale, and improvements in
process efficiency. The expansion of sales to existing customers and the
introduction of new products to new customers have boosted sales of active
ingredients, which are up 27% over the second quarter of last year. Increased
sales of beta glucan were notable as new European customers placed orders
ahead of new product introductions. Ceapro's export sales have continued to
increase despite the continued strengthening of the Canadian dollar over the
last few years.
Our outlook continues to be positive. We are encouraged by strong first
half results and anticipate further revenue growth throughout 2006. Our
objective for the remainder of 2006 is to increase revenues and utilize cash
flow on a discretionary basis to enhance the scale of operations. As a
strategic focus, we continue to concentrate on increasing sales and developing
new opportunities, with emphasis placed on securing new pharmaceutical
customers to use our active ingredients and launching our veterinary products
in the United States. We are introducing CeaProve(R) to North American
corporations as part of corporate wellness programs, and to healthcare
providers internationally for point-of-care diagnosis of diabetes and impaired
glucose tolerance.

About Ceapro Inc.

Ceapro Inc is a Canadian growth stage biotechnology company. Ceapro's
core technology is the extraction of functional, active ingredients from
plants and other renewable resources. We add further value to our extracts by
manufacturing medical and therapeutic products, and by supporting the use of
our extracts in products for human and animal health. We have also introduced
health and wellness services employing our CeaProve(R) diagnostic technology.
Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO.
To learn more about Ceapro, visit our website at www.ceapro.com. Shares
Outstanding: 37,098,670, Recent Close: $0.32.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.


<<
CEAPRO INC.
Consolidated Balance Sheets
                                                    June 30  December 31
                                                       2006         2005
                                                 (Unaudited)    (Audited)
-------------------------------------------------------------------------
ASSETS
CURRENT ASSETS
  Cash                                          $   953,434  $   438,045
  Accounts receivable                               703,617      982,347
  Inventories                                       189,652      228,158
  Prepaid expenses and deposits                      68,102       90,761
-------------------------------------------------------------------------

                                                  1,914,805    1,739,311

PROPERTY AND EQUIPMENT (NET OF ACCUMULATED
 AMORTIZATION)                                      627,735      679,623
-------------------------------------------------------------------------

                                                $ 2,542,540  $ 2,418,934
-------------------------------------------------------------------------
-------------------------------------------------------------------------

LIABILITIES
CURRENT LIABILITIES
  Accounts payable and accrued liabilities      $   673,863  $   284,863
  Deferred revenue                                        -      229,676
  Callable debt                                      59,384       81,584
  Current portion of long-term debt                  35,030       33,519
  Current portion of royalties payable              156,009      106,508
-------------------------------------------------------------------------

                                                    924,286      736,150

DEFERRED ROYALTY REVENUE                            435,930      457,000
EMPLOYEE FUTURE BENEFITS OBLIGATION                 188,344      159,946
LONG-TERM DEBT                                      418,830      436,731
ROYALTIES PAYABLE                                   153,789      167,770
-------------------------------------------------------------------------

                                                  2,121,179    1,957,597
-------------------------------------------------------------------------

SHAREHOLDERS' EQUITY

SHARE CAPITAL                                     2,421,524    2,414,830
CONTRIBUTED SURPLUS                                 114,932      106,888
DEFICIT                                          (2,115,095)  (2,060,381)
-------------------------------------------------------------------------

                                                    421,361      461,337
-------------------------------------------------------------------------

                                                $ 2,542,540  $ 2,418,934
-------------------------------------------------------------------------
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Net (Loss) Income and Deficit
Unaudited

                      Six Months Ended June 30    Quarters Ended June 30
                             2006         2005         2006         2005
----------------------------------------------- -------------------------
Revenue
  Sales               $ 1,844,242  $ 1,420,323  $   945,043  $ 1,031,795
  Cost of goods sold      768,800      640,152      331,687      415,849
----------------------------------------------- -------------------------

  Gross margin          1,075,442      780,171      613,356      615,946
  Royalties, licenses,
   and product
   development fees             -       80,000            -            -
----------------------------------------------- -------------------------

                        1,075,442      860,171      613,356      615,946
----------------------------------------------- -------------------------

Expenses
  General and
   administration         512,386      522,166      276,645      319,575
  Royalties (net)         178,840      177,122       89,287      125,200
  Sales and marketing     154,282      119,586       84,066       67,910
  Amortization             71,962       78,820       36,231       39,925
  Interest on long-term
   debt                    20,576       18,254       10,197       10,897
  Interest on callable
   debt and other           3,932        6,619        2,399        2,813
----------------------------------------------- -------------------------

                          941,978      922,567      498,825      566,320
----------------------------------------------- -------------------------

Income (loss) from
 operations               133,464      (62,396)     114,531       49,626
----------------------------------------------- -------------------------

Other income (expenses)
  Research and product
   development           (148,734)    (227,226)     (77,377)    (183,026)
  Other income
   (expenses)             (39,444)     234,639      (40,582)     234,881
----------------------------------------------- -------------------------

                         (188,178)       7,413     (117,959)      51,855
----------------------------------------------- -------------------------

Income (Loss) before
 income taxes             (54,714)     (54,983)      (3,428)     101,481

Income Taxes
  Current                  84,000       76,000       61,000      102,000
Reduction as a result
 of applying non-capital
 losses carried forward
 against the current
 period's taxable
 income                   (84,000)     (76,000)     (61,000)    (102,000)
----------------------------------------------- -------------------------

NET (LOSS) INCOME FOR
 THE PERIOD               (54,714)     (54,983)      (3,428)     101,481

Deficit, beginning
 of period             (2,060,381)  (2,003,374)  (2,111,667)  (2,159,838)
----------------------------------------------- -------------------------

Deficit, end
 of period            $(2,115,095) $(2,058,357) $(2,115,095) $(2,058,357)
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------

Net (loss) income
 per share:
  Basic               $     (0.00) $     (0.00) $     (0.00) $      0.00
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------
  Diluted             $     (0.00) $     (0.00) $     (0.00) $      0.00
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------



CEAPRO INC.
Consolidated Statements of Cash Flows
Unaudited

                      Six Months Ended June 30    Quarters Ended June 30
                             2006         2005         2006         2005
----------------------------------------------- -------------------------
Operating Activities
  Net (loss) income
   for the period     $   (54,714) $   (54,983) $    (3,428) $   101,481
  Items not affecting
   cash
    Amortization           71,962       78,820       36,231       39,925
    Employee future
     benefits obligation   28,398        6,000       15,498        3,000
    Recognition of
     deferred royalty
     revenue              (21,070)           -      (10,797)           -
    Stock based
     compensation           9,113        1,798        4,557          572
----------------------------------------------- -------------------------

                           33,689       31,635       42,061      144,978

Changes in Non-Cash
 Working Capital Items
  Accounts receivable     278,730     (246,531)     168,594      (79,078)
  Inventories              38,506       75,000       (6,074)      42,728
  Prepaid expenses
   and deposits            22,659       14,467       (2,449)       9,338
  Accounts payable and
   accrued liabilities    389,000      (28,819)     201,113     (152,170)
  Deferred revenue       (229,676)     (80,000)    (114,644)           -
----------------------------------------------- -------------------------

                          532,908     (234,248)     288,601      (34,204)
----------------------------------------------- -------------------------

Investing Activities
  Purchase of property
   and equipment          (20,074)     (62,804)      (9,626)     (14,483)
  Restricted cash for
   the purchase of
   property and equipment       -       49,880            -       11,252
----------------------------------------------- -------------------------

                          (20,074)     (12,924)      (9,626)      (3,231)
----------------------------------------------- -------------------------

Financing Activities
  Repayment of long-term
   debt                   (16,390)     (12,551)      (8,284)      (7,586)
  Repayment of callable
   debt                   (22,200)     (19,766)     (11,206)      (9,976)
  Repayment of convertible
   debenture                    -      (20,000)           -      (20,000)
  Proceeds from issuance
   of share capital             -      204,800            -            -
  Proceeds from exercise of
   stock options            5,625        9,500            -            -
  Increase (decrease) in
   royalties payable       35,520       99,239      (64,307)      47,318
----------------------------------------------- -------------------------

                            2,555      261,222      (83,797)       9,756
----------------------------------------------- -------------------------

Increase (decrease)
 in cash                  515,389       14,050      195,178      (27,679)
Cash at beginning of
 period                   438,045       96,266      758,256      137,995
Cash at end of period $   953,434  $   110,316  $   953,434  $   110,316
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------

Supplementary
 information:
  Interest paid       $    23,371  $    28,325  $    11,460  $    14,583
  Royalties paid      $   164,393  $    77,883  $   164,393  $    77,883

>>
%SEDAR: 00010110E

Ceapro on 6ix

Story so far

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases